Bayer supports demining in Ukraine with donation to non-profit "Fondation suisse de déminage"

BayerBayer supports the humanitarian non-profit organization "Fondation suisse de déminage" (FSD) in their mission to demine land that was contaminated by mines and unexploded devices since the onset of the war in Ukraine. A donation of 825,000 euros will be dedicated to purchasing a large-size mechanical mine clearance machine. The machine is able to process large areas of land such as farmland.

The mine clearance machine is currently being maintained and prepared for its deployment in Ukraine, planned for this fall. It will support FSD's demining operations funded by the United States Department of State. The specific areas of operation of the machine will be coordinated between FSD and Ukrainian authorities.

"As landmines and explosive devices pose a life threat to people in Ukraine, we are convinced that our donation to FSD is an important humanitarian contribution to the safety of the Ukrainian civil society. Further, by clearing farmland, it will allow farmers to grow food safely, gain an income and help to relieve the tense situation around global food security. Large parts of the global south depend on food exports from Ukraine," says Bayer CEO Werner Baumann.

"This large demining machine will play a crucial role in accelerating the demining process in Ukraine," says Hansjoerg Eberle, Director of FSD. "It will enable the rapid removal of vegetation cover to allow our detectors access to the surface. In addition, it will expedite the ‘technical survey’ of potentially contaminated land. This key phase of humanitarian demining aims at getting a clear picture of the contamination so as to allocate the clearance resources in the most efficient manner."

Mine clearance is of vital importance for Ukraine. Since the beginning of the war, large areas of land have been contaminated fully or partially with landmines and unexploded or abandoned munitions, thereof large parts of agricultural land where farming is currently not possible. To help Ukrainian civilians, including farmers, stay safe and secure the upcoming harvest without risking their lives, clearing the ground of explosive ordnance is vital.

So far, only one large demining machine is used to support demining operations throughout the country. While this type of large machine is hardened against anti-vehicle mines and unexploded ordnance, it is not impervious to them; correct use of the machine by specifically trained operators is of paramount importance. Also, areas where the machine has worked will still be subject to follow-ups by manual deminers and to internal and external quality control measures.

The donation to FSD to purchase the mine clearance machine is one of many humanitarian actions which Bayer has initiated. Since the start of the war in February, the company donated a total of over 10 million euros so far. This includes establishing a disaster relief fund and product donations, including antibiotics and oncology therapeutics.

Further, Bayer is fully committed to Ukraine's future through investing in the country and supporting President Zelensky’s rebuilding plan - called United24. The company aims to continue making significant investments in the country over the next decade - mainly to rebuild Ukraine´s agricultural system. As a start, to cover the corn seed demand in Ukraine and beyond, Bayer will invest more than 30 million Euros from 2022 onwards in the Pochuiky seed plant. This investment includes raising the capacity of seeds dryer, extra field equipment, additional storage facilities - and new employment opportunities in the region. Bayer will also support the rebuilding of Ukraine's hospital and public health infrastructure.

About Bayer

Bayer is a global enterprise with core competencies in the life science fields of health care and nutrition. Its products and services are designed to help people and planet thrive by supporting efforts to master the major challenges presented by a growing and aging global population. Bayer is committed to drive sustainable development and generate a positive impact with its businesses. At the same time, the Group aims to increase its earning power and create value through innovation and growth. The Bayer brand stands for trust, reliability and quality throughout the world. In fiscal 2021, the Group employed around 100,000 people and had sales of 44.1 billion euros. R&D expenses before special items amounted to 5.3 billion euros.

About FSD

FSD works for a world free of mines and other dangerous remnants of war, where women, men and children can live in a safe and sustainable environment. FSD is a non-governmental humanitarian organization founded in 1997 and based in Geneva. Its core profession is mine action but the organization is also active in other humanitarian sectors. Since foundation, FSD has been active in 29 countries and has returned 450 km2 of cleared land to communities, with nearly 1.4 million items of explosive ordnance destroyed.

FSD has been active in Ukraine since mid-2015, working in the Donbass area until 24 February 2022. During this period, FSD has implemented projects involving explosive ordnance risk education, mined area survey, minefield clearance and battle area clearance. For last two years, FSD has also been involved in a project to support the smaller schools and kindergartens in the forgotten communities along the old contact line in the Donbass. Since June, FSD has shifted location to the Chernihiv Oblast (province), to the north of Kyiv, and has restarted clearance, survey and explosive ordnance risk education operations with enlarged capacities.

Most Popular Now

FDA grants Breakthrough Therapy Designation to Pfi…

Pfizer Inc. (NYSE:PFE) today announced that its investigational Group B Streptococcus (GBS) vaccine candidate, GBS6 or PF-06760805, received Breakthrough Therapy Designat...

Novartis invests in early technical development ca…

Novartis today announced it is investing in next-generation biotherapeutics with the creation of a fully integrated, dedicated USD 300m scientific environment that will b...

Pfizer and BioNTech receive positive CHMP opinion …

Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) announced a 30-µg booster dose of their Omicron BA.4/BA.5 bivalent-adapted COVID-19 vaccine (COMIRNATY® Original/Om...

Malaria booster vaccine shows durable high efficac…

Researchers from the University of Oxford and their partners have today reported new findings from their Phase 2b trial following the administration of a booster dose of ...

Strict COVID lockdowns in France improved cardiova…

A new paper in European Heart Journal - Digital Health, published by Oxford University Press, indicates that social-distancing measures like total lockdown have a measura...

U.S. clinical trial evaluating antiviral for monke…

A Phase 3 clinical trial evaluating the antiviral tecovirimat, also known as TPOXX, is now enrolling adults and children with monkeypox infection in the United States. St...

Stem cell-gene therapy shows promise in ALS safety…

Cedars-Sinai investigators have developed an investigational therapy using support cells and a protective protein that can be delivered past the blood-brain barrier. This...

Drug turns cancer gene into "eat me" fla…

Tumor cells are notoriously good at evading the human immune system; they put up physical walls, wear disguises and handcuff the immune system with molecular tricks. Now...

Mucosal antibodies in the airways protect against …

High levels of mucosal antibodies in the airways reduce the risk of being infected by omicron, but many do not receive detectable antibodies in the airways despite three ...

WHO grants prequalification to GSK's Mosquirix - t…

GSK plc (LSE/NYSE: GSK) announced that the World Health Organization (WHO) has awarded prequalification to Mosquirix (also known as RTS,S/AS01), GSK's groundbreaking mala...

Bird's enzyme points toward novel therapies

Thank the rare crested ibis for a clue that could someday help our bodies make better drugs. The species of bird is the only one known to naturally produce an enzyme ...

WHO strongly advises against antibody treatments f…

The antibody drugs sotrovimab and casirivimab-imdevimab are not recommended for patients with COVID-19, says a WHO Guideline Development Group of international experts in...